The DOI matches its Crossref record.
Is It Time To Change Fluoroquinolone Breakpoints for Salmonella spp.?
Open accessAbstract
Fluoroquinolones are the drug of choice for treatment of invasive gastrointestinal infections in many parts of the world. Salmonella enterica is one of the most common causes of human gastroenteritis worldwide. Nontyphoidal Salmonella infections are primarily caused by consumption of contaminated foods primarily of animal origin, whereas S. enterica serovar Typhi and Paratyphi infections are spread directly or indirectly from human feces. Since the early 1990s, fluoroquinolones have in many countries been licensed for use in food production animals. The concomitant emergence and increased incidence of quinolone-resistant Salmonella strains have been an issue of intense worldwide debate. In members of the family Enterobacteriaceae, resistance to quinolones is most commonly acquired by mutations in two steps. One mutation in the gyrA gene mediates full resistance to narrow-spectrum quinolones, such as nalidixic acid and decreased susceptibility to fluoroquinolones (3, 18). A second mutation in either gyrA or gyrB genes mediates full resistance to fluoroquinolones. The current National Committee for Clinical Laboratory standards (NCCLS) breakpoint for resistance to the fluoroquinolone ciprofloxacin is ≥4 μg/ml, while the breakpoint for resistance to its veterinary equivalent, enrofloxacin, is ≥2 μg/ml (14, 15). Even though the NCCLS does not provide specific breakpoints for bacteria associated with gastrointestinal infections, the current breakpoints are widely used by clinicians, veterinarians, microbiologists, and others involved with the issues involving selection for fluoroquinolone resistance. Several studies have shown that resistance to nalidixic acid and decreased susceptibility to fluoroquinolones have increased among Salmonella spp. from food animals and infections in humans (8, 10, 13, 19-21). Some have used this as an argument against the continued usage of fluoroquinolones for food animals. Defenders of the continued usage of fluoroquinolones for food animals argue that on the basis of the NCCLS breakpoint, there is still very limited “clinical” fluoroquinolone resistance among Salmonella strains, despite several years of fluoroquinolone use in food animal production. With this letter, we do not want to get into the debate regarding the continued usage of fluoroquinolones among food animals. However, we wish to stress the importance of establishing a common breakpoint as the basis for evaluating susceptibility data and interpreting these data in a clinical context. Isolates with a single mutation in gyrA are to some extent refractory to the bactericidal effect of fluoroquinolones (2; J. D. Knudsen, R. Skov, P. Gerner-Smidt, L. V. Pallesen, and N. Frimodt-Moller, Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-2091, 2001). In our opinion, there is now compelling evidence that the treatment efficacy of fluoroquinolones is reduced in humans infected with strains of Salmonella enterica that demonstrate what is regarded as decreased susceptibility to fluoroquinolones. Thus, the use of the NCCLS breakpoint at ≥4 μg/ml for ciprofloxacin may have the effect of obscuring the true occurrence of resistance to quinolones among Salmonella strains. Indeed, in several cases, decreased susceptibility to fluoroquinolones has only been detected on the basis of resistance to nalidixic acid after the patient has failed to respond to treatment with ciprofloxacin. A number of reported cases of infections with S. enterica serovar Typhi and nontyphoid Salmonella in humans are shown in Table Table1.1. One observation common to all reports is that fluoroquinolones were ineffective in treating patients who were infected with isolates for which the MICs of fluoroquinolones were between 0.06 and 2 mg/liter. In five case reports on nontyphoid Salmonella infections, resistance to nalidixic acid and decreased susceptibility to ciprofloxacin (MIC, 0.125 to 2 mg/liter) developed during therapy. Helms et al. (7) reported that patients infected with isolates for which MICs were between 0.06 and 0.38 mg/liter were five times more likely to die within 2 years after infection than patients infected with isolates for which MICs were lower. In the latter report, all isolates were isolated before initial therapy, and it is highly probable that the patients were originally infected with isolates with decreased susceptibility to fluoroquinolones. TABLE 1. Different studies reporting treatment failures in patients infected with Salmonella enterica serovar Typhi and non-Typhi Salmonella isolates with decreased susceptibility to fluoroquinolones In conclusion, the available literature has demonstrated that when patients are infected with Salmonella isolates with decreased susceptibility to fluoroquinolones, treatment failures may occur. Thus, to reduce the risk for humans, we recommend that for Salmonella, a breakpoint of ≥0.125 μg/ml for fluoroquinolones should be used when evaluating both labora
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Antimicrobial resistance: a global multifaceted phenomenon
Prestinaci, F., Pezzotti, P., & Pantosti, A. (2015) · Pathogens and Global Health · doi:10.1179/2047773215y.0000000030 · Cited by 3,296
Crump, J. A., Sjölund-Karlsson, M., Gordon, M. A., & Parry, C. M. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00002-15 · Cited by 1,156
Angulo, F. J., Nargund, V. N., & Chiller, T. C. (2004) · Journal of Veterinary Medicine, Series B · doi:10.1111/j.1439-0450.2004.00789.x · Cited by 355
Metadata
- Authors
- Aarestrup, F. M., Wiuff, C., Mølbak, K., & Threlfall, E. J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2003-02
- Volume
- 47
- Issue
- 2
- Pages
- 827-829
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2028103501
- Cited by
- 182
- References
- 0
- FWCI
- 32.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is It Time To Change Fluoroquinolone Breakpoints for Salmonella spp.? https://app.cochat.ai/papers/10.1128/aac.47.2.827-829.2003
- The paper
- Aarestrup, F. M., Wiuff, C., Mølbak, K., & Threlfall, E. J. (2003). Is It Time To Change Fluoroquinolone Breakpoints for Salmonella spp.? Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.47.2.827-829.2003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.